Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers
Background The dismal clinical outcome of relapsed/refractory (R/R) T cell acute lymphoblastic leukemia (T-ALL) highlights the need for innovative targeted therapies. Although chimeric antigen receptor (CAR)-engineered T cells have revolutionized the treatment of B cell malignancies, their clinical...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| פורמט: | Article |
| שפה: | English |
| יצא לאור: |
BMJ Publishing Group
2022-12-01
|
| סדרה: | Journal for ImmunoTherapy of Cancer |
| גישה מקוונת: | https://jitc.bmj.com/content/10/12/e005333.full |